ArticleJCEM case reports2026
Hungry bone syndrome-like state following denosumab in a patient with multiple myeloma.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Denosumab-induced hypocalcemia is a well-recognized entity, especially in patients with renal impairment or vitamin D deficiency. Hungry bone syndrome (HBS), characterized by prolonged hypocalcemia and hypophosphatemia due to rapid skeletal remineralization, is classically seen post-parathyroidectomy and is rare in purely osteolytic malignancies such as multiple myeloma (MM). A 76-year-old man with newly diagnosed MM (extensive osteolytic skeletal involvement) developed severe, prolonged hypocalcemia following two doses of denosumab administered one month apart. Pre-denosumab evaluation showed elevated creatinine and calcium, sufficient vitamin D, and suppressed parathyroid hormone. One week after the second dose, he was found to have profound hypocalcemia, hypophosphatemia, hypomagnesemia, and QT interval prolongation. Despite aggressive oral calcium, calcitriol, and magnesium supplementation, hypocalcemia, hypophosphatemia, and hypomagnesemia persisted. Subsequent evaluation revealed secondary hyperparathyroidism and persistently elevated bone turnover markers (both formation and resorption). Low urinary calcium excretion supported the presence of a skeletal mineral sink. This case highlights an HBS-like state after denosumab-induced osteoclast inhibition in high-turnover osteolytic lesions of MM. Renal impairment and extensive skeletal involvement were predisposing factors. Persistence of elevated resorption marker suggests incomplete suppression of bone resorption due to secondary hyperparathyroidism and renal impairment. Close monitoring and anticipatory mineral supplementation are essential after denosumab in high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.